Press Releases.

Month Year

Month Year

Investor Alerts

April 30, 2024

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
March 21, 2024

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
March 12, 2024

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
March 12, 2024

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
January 02, 2024

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
November 22, 2023

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 09, 2023

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
November 02, 2023

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
October 19, 2023

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
September 20, 2023

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Show per page